CLINICAL_TRIALS ClinicalTrials.gov record update

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04566393
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:33.245683+00:00
Published At: 2026-01-28T00:00:00+00:00
Record Updated At: 2026-01-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pancreatic Cancer", "Small Bowel Cancer", "Colorectal Cancer", "Melanoma", "Non Small Cell Lung Cancer", "Thyroid Cancer", "Bladder Cancer", "Head and Neck Cancer", "Gastric Cancer", "Esophageal Cancer", "Cholangiocarcinoma", "Ovarian Cancer", "Hepatocellular Carcinoma", "Glioblastoma", "MAPK Gene Mutation", "KRAS Activating Mutation", "BRAF Gene Mutation", "NRAS Gene Mutation", "HRAS Gene Mutation", "MEK Mutation", "ERK Mutation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-28"
protocolSection.identificationModule.nctId: "NCT04566393"
protocolSection.identificationModule.officialTitle: "Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies"
protocolSection.statusModule.overallStatus: "AVAILABLE"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.